Beginning on October 1, 2024, drug companies submitting NDAs, GDAs, and minor variation applications in Singapore must also incorporate GMP Compliance Evidence for their drug substances. There is a grace period until September 30, 2024, but Singapore’s HSA recommends that drug substance manufacturers submit GMP compliance evidence as soon as possible.
GMP compliance evidence can include one of three things – First, a GMP certificate, a GMP inspection report, or a written statement from the PIC/S authority that issued the GMP certificate for the related drug substance. Alternatively, second, a registrant certificate of the valid API for the drug substance recorded on the EVDRAGMP. Or, in situations where one of the two conditions above cannot be met, a third option is to provide the monograph of the European Pharmacopeia (CEP) issued by the EDQM for a valid Certificate of Suitability for the drug substance. Please note drug applications that do not have one of the required drug substance GMP evidences, will be rejected by Singapore’s HSA starting from the fall of next year.
Regulatory Affairs Professionals Society (RAPS)5635 Fishers Lane, Suite 400Rockville, Maryland 20852
email@example.com+1 301 770 2920
JoinMy RAPS DashboardLearn More